| [1] |
|
| [2] |
|
| [3] |
National Comprehensive Cancer Network. (NCCN) Clinical practice guidelines in oncology. Ovarian cancer/fallopian tube cancer/primary peritoneal cancer version: 1.2025 (EB/OL). [2025-04-18].
URL
|
| [4] |
|
| [5] |
Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a Meta-analysis [J]. J Clin Oncol, 2023, 41(25): 4065-4076. DOI: 10.1200/JCO.22.02765.
|
| [6] |
Horowitz NS, Miller A, Rungruang B, et al. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182 [J]. J Clin Oncol, 2015, 33(8): 937-943. DOI: 10.1200/JCO.2014.56.3106.
|
| [7] |
Kalampokas E, Young H, Bednarek A, et al. Surgical outcomes and morbidity after radical surgery for ovarian cancer in Aberdeen Royal Infirmary, the Northeast of Scotland Gynaecologic Oncology Centre [J]. Anticancer Res, 2018, 38(2): 923-928. DOI: 10.21873/anticanres.12304.
|
| [8] |
Winter WE, Maxwell GL, Tian C, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage Ⅳ epithelial ovarian cancer: a Gynecologic Oncology Group Study [J]. J Clin Oncol, 2008, 26(1): 83-89. DOI: 10.1200/JCO.2007.13.1953.
|
| [9] |
Aletti GD, Eisenhauer EL, Santillan A, et al. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment [J]. Gynecol Oncol, 2011, 120(1): 23-28. DOI: 10.1016/j.ygyno.2010.09.010.
|
| [10] |
Lee YJ, Lee JY, Nam EJ, et al. Rethinking radical surgery in interval debulking surgery for advanced-stage ovarian cancer patients undergoing neoadjuvant chemotherapy [J]. J Clin Med, 2020, 9(4): 1235. DOI: 10.3390/jcm9041235.
|
| [11] |
Yao T, DeJong SR, McGree ME, et al. Frailty in ovarian cancer identified the need for increased postoperative care requirements following cytoreductive surgery [J]. Gynecol Oncol, 2019, 153(1): 68-73. DOI: 10.1016/j.ygyno.2018.12.025.
|
| [12] |
Thrall MM, Goff BA, Symons RG, et al. Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly [J]. Obstet Gynecol, 2011, 118(3): 537-547. DOI: 10.1097/AOG.0b013e31822a6d56.
|
| [13] |
|
| [14] |
Chang SJ, Bristow RE, Chi DS, et al. Role of aggressive surgical cytoreduction in advanced ovarian cancer [J]. J Gynecol Oncol, 2015, 26(4): 336-342. DOI: 10.3802/jgo.2015.26.4.336.
|
| [15] |
Tseng JH, Cowan RA, Zhou Q, et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete gross resection rates independently lead to increased progression-free and overall survival? [J]. Gynecol Oncol, 2018, 151(1): 24-31. DOI: 10.1016/j.ygyno.2018.08.014.
|
| [16] |
Nishikimi K, Tate S, Matsuoka A, et al. Aggressive surgery could overcome the extent of initial peritoneal dissemination for advanced ovarian, fallopian tube, and peritoneal carcinoma [J]. Sci Rep, 2020, 10(1): 21307. DOI: 10.1038/s41598-020-78296-0.
|
| [17] |
Aletti GD, Dowdy SC, Podratz KC, et al. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer [J]. Am J Obstet Gynecol, 2007, 197(6): 676. e1-e7. DOI: 10.1016/j.ajog.2007.10.495.
|
| [18] |
Narasimhulu DM, Kumar A, Weaver AL, et al. Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer [J]. Gynecol Oncol, 2019, 155(1): 58-62. DOI: 10.1016/j.ygyno.2019.08.004.
|
| [19] |
Narasimhulu DM, Kumar A, Weaver AL, et al. Less guessing, more evidence in identifying patients least fit for cytoreductive surgery in advanced ovarian cancer: a triage algorithm to individualize surgical management [J]. Gynecol Oncol, 2020, 157(3): 572-577. DOI: 10.1016/j.ygyno.2020.03.024.
|
| [20] |
Jiang C, Li Z. Performance validation of the Mayo triage algorithm applied to individualize surgical management of advanced epithelial ovarian cancer [J]. Gynecol Oncol, 2021, 162(2): 339-344. DOI: 10.1016/j.ygyno.2021.06.003.
|
| [21] |
Narasimhulu DM, Thannickal A, Kumar A, et al. Appropriate triage allows aggressive primary debulking surgery with rates of morbidity and mortality comparable to interval surgery after chemotherapy [J]. Gynecol Oncol, 2021, 160(3): 681-687. DOI: 10.1016/j.ygyno.2020.12.026.
|